AstraZeneca has added a late-stage rare disease therapy to its pipeline, buying France’s Amolyt Pharma and its hypoparathyroidism drug eneboparatide for $800 million upfront. The bolt-on deal, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback